Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Lyell Immunopharma was $256.52 million, down 28.0% year-over-year; for FY2025, it was $269.44 million, down 24.9% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 4.2% (FY2020 to FY2025).
• In prior years, Lyell Immunopharma's Operating Expenses was $358.82 million in FY2024 (+45.2%), $247.14 million in FY2023 (-9.1%), $271.74 million in FY2022 (+20.5%) and $225.43 million in FY2021 (+2.6%).
• Quarterly Operating Expenses has run from a low of $37.27 million in Q3 2025 to a high of $201.16 million in Q4 2024 over five years.
• On a year-over-year basis, Operating Expenses increased in three of the last eight quarters, with growth averaging 16.6%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2024, with growth of 238.0%; the weakest was Q4 2025, with a decline of 36.5%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $44.26 million (Q1 2026), $127.65 million (Q4 2025) and $37.27 million (Q3 2025).